[1]
|
International Diabetes Federation (2013) IDF Diabets Atlas. 6th Edition, International Diabetes Federation, Brussels.
|
[2]
|
Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., et al. (2015) Association of Cardiometabolic Multimorbidity with Mortality. JAMA, 314, 52-60. https://doi.org/10.1001/jama.2015.7008
|
[3]
|
From, A.M., Scott, C.G. and Chen, H.H. (2010) The Development of Heart Failure in Patients with Diabetes Mellitus and Pre-Clinical Diastolic Dysfunction a Population-Based Study. Journal of the American College of Cardiology, 55, 300-305. https://doi.org/10.1016/j.jacc.2009.12.003
|
[4]
|
Dawson, A., Morris, A.D. and Struthers, A.D. (2005) The Epidemiology of Left Ventricular Hypertrophy in Type 2 Diabetes Mellitus. Diabetologia, 48, 1971-1979. https://doi.org/10.1007/s00125-005-1896-y
|
[5]
|
Stratton, I.M., Adler, A.I., Neil, H.A., Matthews, D.R., Manley, S.E., Cull, C.A., et al. (2000) Association of Glycaemia with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational Study. BMJ, 321, 405-412. https://doi.org/10.1136/bmj.321.7258.405
|
[6]
|
Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. (2017) Canagliflozin Andcardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine, 377, 644-657.
https://doi.org/10.1056/NEJMoa1611925
|
[7]
|
Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., et al. (2019) Dapagliflozin and Cardiovascularoutcomes in Type 2 Diabetes. New England Journal of Medicine, 380, 347-357.
https://doi.org/10.1056/NEJMoa1812389
|
[8]
|
Perkovic, V., Jardine, M.J., Neal, B., Bompoint, S., Heerspink, H.J.L., Charytan, D.M., et al. (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 380, 2295-306.
https://doi.org/10.1056/NEJMoa1811744
|
[9]
|
Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 373, 2117-2128.
https://doi.org/10.1056/NEJMoa1504720
|
[10]
|
中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018 [J] .中华心血管病杂志, 2018, 46(10): 760-789.
|
[11]
|
Abdi-Ali, A., Miller, R.J.H., Southern, D., Zhang, M., Mikami, Y., Knudtson, M., et al. (2018) LV Mass Independently Predicts Mortality and Need for Future Revascularization in Patients Undergoing Diagnostic Coronary Angiography. JACC: Cardiovascular Imaging, 11, 423-433. https://doi.org/10.1016/j.jcmg.2017.04.012
|
[12]
|
Mathew, J., Sleight, P., Lonn, E., Johnstone, D., Pogue, J., Yi, Q.L., et al. (2001) Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitorramipril. Circulation, 104, 1615-1621. https://doi.org/10.1161/hc3901.096700
|
[13]
|
Sattar, N., McLaren, J., Kristensen, S.L., Preiss, D. and McMurray, J.J. (2016) SGLT2 Inhibitionand Cardiovascular Events: Why did EMPA-REG Outcomes Surprise and What Were the Likely Mechanisms? Diabetologia, 59, 1333-1339.
https://doi.org/10.1007/s00125-016-3956-x
|
[14]
|
Shubrook, J.H., Bokaie, B.B. and Adkins, S.E. (2015) Empagliflozin in the Treatment of Type 2 Diabetes: Evidence to Date. Drug Design, Development and Therapy, 9, 5793-5803. https://doi.org/10.2147/DDDT.S69926
|
[15]
|
Chilton, R., Tikkanen, I., Cannon, C.P., Crowe, S. Woerle, H.J., Broedl, U.C., et al. (2015) Effects of Empagliflozin on Blood Pressure and Markers of Arterial Stiffness and Vascular Resistance in patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 17, 1180-1193. https://doi.org/10.1111/dom.12572
|
[16]
|
Sano, M. (2018) A New Class of Drugs for Heart Failure: SGLT2 Inhibitors Reduce Sympathetic Overactivity. Journal of Cardiology, 71, 471-476. https://doi.org/10.1016/j.jjcc.2017.12.004
|
[17]
|
Brown, A.J.M., Lang, C., McCrimmon, R. and Struthers, A. (2017) Does Dapagliflozin Regress Left Ventricularhypertrophy in Patients with Type 2 Diabetes? A Prospective, Double-Blind, Randomised, Placebo-Controlled Study. BMC Cardiovascular Disorders, 17, Article No. 229. https://doi.org/10.1186/s12872-017-0663-6
|
[18]
|
Verma, S., Garg, A., Yan, A.T., Gupta, A.K., Al-Omran, M., Sabongui, A., et al. (2016) Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals with Diabetes: An Important Clue to the EMPA- REGOUTCOME Trial? Diabetes Care, 39, e212-e213. https://doi.org/10.2337/dc16-1312
|
[19]
|
Matsutani, D., Sakamoto, M., Kayama, Y., Takeda, N., Horiuchi, R. and Utsunomiya, K. (2018) Effect of Canagliflozin on Left Ventricular Diastolic Function in Patients with Type 2 Diabetes. Cardiovascular Diabetology, 17, Article No. 73. https://doi.org/10.1186/s12933-018-0717-9
|
[20]
|
Soga, F., Tanaka, H., Tatsumi, K., Mochizuki, Y., Sano, H., Toki, H., Matsumoto, K., et al. (2018) Impact of Dapagliflozin on Left Ventricular Diastolicfunction of Patients with Type 2 Diabetic Mellitus with Chronic Heart Failure. Cardiovascular Diabetology, 17, Article No.132. https://doi.org/10.1186/s12933-018-0775-z
|
[21]
|
Sakai, T. and Miura, S. (2018) Abstract 17041: Effectof Sodium-Glucose Cotransporter 2 Inhibitor on Vascular Endothelial Function and Diastolic Function in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF). Circulation, 136, Article ID: A17041.
|
[22]
|
Tochiya, M., Makino, H., Tamanaha, T., Matsuo, M., Hishida, A., Koezuka, R., et al. (2020) Effect of Tofogliflozin on Cardiac and Vascular Endothelial Function in Patients with Type 2 Diabetes and Heart Diseases: A Pilot Study. Journal of Diabetes Investigation, 11, 400-404. https://doi.org/10.1111/jdi.13122
|